Meridian ID 肥胖症临床试验
8项针对 肥胖症的研究正在 Meridian及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
招募中3 期
- Solaris Clinical Research, Meridian
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
招募中3 期
- Velocity Clinical Research - Boise, Meridian
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
招募中3 期
- High Desert Heart and Vascular, Meridian
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
招募中3 期欢迎健康志愿者
- ACCOMPLISH-2 Research Site, Meridian
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
招募中3 期
- Solaris Clinical Research, Meridian
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
招募中3 期
- Solaris Clinical Research, Meridian
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
招募中3 期
- High Desert Heart and Vascular PLLC, Meridian
- St. Luke's Idaho Cardiology Associates, Meridian
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
招募中3 期
- ACCOMPLISH-1 Research Site, Meridian
其他城市的 肥胖症试验
- Houston, TX44 项研究
- Chicago, IL42 项研究
- New York City, NY40 项研究
- San Antonio, TX39 项研究
- Washington, DC33 项研究
- Dallas, TX31 项研究
- Orlando, FL29 项研究
- Boston, MA28 项研究
- Miami, FL27 项研究
- Las Vegas, NV27 项研究
- Atlanta, GA25 项研究
- Jacksonville, FL25 项研究
Meridian的其他研究
- 前列腺癌7 项研究
- 超重7 项研究
- 急性髓系白血病6 项研究
- 动脉粥样硬化5 项研究
- 结直肠癌4 项研究
- 非小细胞肺癌4 项研究
- 肺癌4 项研究
- 心血管疾病3 项研究
- 头颈鳞状细胞癌3 项研究
- 湿疹3 项研究
- 子宫内膜癌3 项研究
- 黑色素瘤3 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月1日。每项研究自行设定入选标准,由研究团队决定谁能参与。